IGFBP1hiWNT3Alo Subtype in Esophageal Cancer Predicts Response and Prolonged Survival with PD-(L)1 Inhibitor
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Analysis of 3 Public Esophageal Cancer Cohorts from TCGA and GEO
2.2. Analysis of 2 Clinical Esophageal Cancer Cohorts from BJCH and BJIM
2.3. Immunohistochemistry Analysis of the BJCH Cohort
2.4. Next-Generation Sequencing and Analysis of the BJIM Cohort
2.5. Grouping and Marker Gene Mining Based on WNT Signaling
2.6. Gene Set Enrichment Analysis
2.7. Immune Cell Infiltration and Molecular Characterization
2.8. Statistical Analysis
3. Results
3.1. Patients with Esophageal Cancer Could Be Stratified into 3 Clusters Based on WNT Signaling
3.2. The Cluster 3 of Marker Genes Are IGFBP1hi and WNT3Alo
3.3. Molecular Characterization of the IGFBP1hiWNT3Alo Subtype
3.4. The IGFBP1hiWNT3Alo Subtype Correlates with Poor Prognosis in TCGA Esophageal Cancer Patients
3.5. Validation That the IGFBP1hiWNT3Alo Subtype Is Associated with Poor Prognosis in BJCH Esophageal Cancer Patients
3.6. The IGFBP1hiWNT3Alo Subtype Is Associated with Good Immunotherapy Response and Prognosis in Esophageal Cancer
3.7. Characterization of the Immune Cell Infiltration and Immune Features of the IGFBP1hiWNT3Alo Subtype
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Cao, W.; Chen, H.D.; Yu, Y.W.; Li, N.; Chen, W.Q. Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020. Chin. Med. J. 2021, 134, 783–791. [Google Scholar] [CrossRef]
- Boonstra, J.J.; Kok, T.C.; Wijnhoven, B.P.; van Heijl, M.; Henegouwen, M.I.V.B.; Kate, F.J.T.; Siersema, P.D.; Dinjens, W.N.; van Lanschot, J.J.; Tilanus, H.W.; et al. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: Long-term results of a randomized controlled trial. BMC Cancer 2011, 11, 181. [Google Scholar] [CrossRef] [Green Version]
- Kojima, T.; Shah, M.A.; Muro, K.; Francois, E.; Adenis, A.; Hsu, C.H.; Doi, T.; Moriwaki, T.; Kim, S.B.; Lee, S.H.; et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J. Clin. Oncol. 2020, 38, 4138–4148. [Google Scholar] [CrossRef] [PubMed]
- Kelly, R.J.; Ajani, J.A.; Kuzdzal, J.; Zander, T.; Van Cutsem, E.; Piessen, G.; Mendez, G.; Feliciano, J.; Motoyama, S.; Lievre, A.; et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N. Engl. J. Med. 2021, 384, 1191–1203. [Google Scholar] [CrossRef]
- Yamamoto, S.; Kato, K.; Daiko, H.; Kojima, T.; Hara, H.; Abe, T.; Tsubosa, Y.; Nagashima, K.; Aoki, K.; Mizoguchi, Y.; et al. Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E). Future Oncol. 2020, 16, 1351–1357. [Google Scholar] [CrossRef]
- Xing, W.; Zhao, L.; Fu, X.; Liang, G.; Zhang, Y.; Yuan, D.; Li, Z.; Gao, Q.; Zheng, Y.; Written on Henan Cancer Hospital Thoracic Oncology Group. A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma. J. Thorac. Dis. 2020, 12, 6861–6867. [Google Scholar] [CrossRef]
- Zheng, Y.; Liu, X.B.; Sun, H.B.; Xu, J.; Shen, S.; Ba, Y.F.; Yan, M.; Qin, Z.; Liu, B.X.; Wang, Z.F.; et al. A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909). Ann. Transl. Med. 2021, 9, 73. [Google Scholar] [CrossRef]
- Huang, J.; Xu, J.; Chen, Y.; Zhuang, W.; Zhang, Y.; Chen, Z.; Chen, J.; Zhang, H.; Niu, Z.; Fan, Q.; et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): A multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020, 21, 832–842. [Google Scholar] [CrossRef]
- Shitara, K.; Van Cutsem, E.; Bang, Y.J.; Fuchs, C.; Wyrwicz, L.; Lee, K.W.; Kudaba, I.; Garrido, M.; Chung, H.C.; Lee, J.; et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020, 6, 1571–1580. [Google Scholar] [CrossRef]
- Marabelle, A.; Fakih, M.; Lopez, J.; Shah, M.; Shapira-Frommer, R.; Nakagawa, K.; Chung, H.C.; Kindler, H.L.; Lopez-Martin, J.A.; Miller, W.H.; et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020, 21, 1353–1365. [Google Scholar] [CrossRef]
- Gibney, G.T.; Weiner, L.M.; Atkins, M.B. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016, 17, e542–e551. [Google Scholar] [CrossRef] [Green Version]
- Cai, H.; Li, M.; Deng, R.; Wang, M.; Shi, Y. Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy. Biomark. Res. 2022, 10, 67. [Google Scholar] [CrossRef]
- Galluzzi, L.; Yamazaki, T.; Kroemer, G. Linking cellular stress responses to systemic homeostasis. Nat. Rev. Mol. Cell Biol. 2018, 19, 731–745. [Google Scholar] [CrossRef]
- Spranger, S.; Bao, R.; Gajewski, T.F. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 2015, 523, 231–235. [Google Scholar] [CrossRef]
- Spranger, S.; Gajewski, T.F. A new paradigm for tumor immune escape: Beta-catenin-driven immune exclusion. J. Immunother. Cancer 2015, 3, 43. [Google Scholar] [CrossRef] [Green Version]
- Harding, J.J.; Nandakumar, S.; Armenia, J.; Khalil, D.N.; Albano, M.; Ly, M.; Shia, J.; Hechtman, J.F.; Kundra, R.; El Dika, I.; et al. Prospective genotyping of hepatocellular carcinoma: Clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin. Cancer Res. 2019, 25, 2116–2126. [Google Scholar] [CrossRef] [Green Version]
- Luke, J.J.; Bao, R.; Sweis, R.F.; Spranger, S.; Gajewski, T.F. WNT/beta-catenin pathway activation correlates with immune exclusion across human cancers. Clin. Cancer Res. 2019, 25, 3074–3083. [Google Scholar] [CrossRef] [Green Version]
- Chen, L.; Zhou, Q.; Liu, J.; Zhang, W. CTNNB1 alternation is a potential biomarker for immunotherapy prognosis in patients with hepatocellular carcinoma. Front. Immunol. 2021, 12, 759565. [Google Scholar] [CrossRef]
- Niehrs, C. The complex world of WNT receptor signalling. Nature reviews. Mol. Cell Biol. 2012, 13, 767–779. [Google Scholar] [CrossRef]
- Akaboshi, S.; Watanabe, S.; Hino, Y.; Sekita, Y.; Xi, Y.; Araki, K.; Yamamura, K.; Oshima, M.; Ito, T.; Baba, H.; et al. HMGA1 is induced by Wnt/beta-catenin pathway and maintains cell proliferation in gastric cancer. Am. J. Pathol. 2009, 175, 1675–1685. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jones, J.; Gockerman, A.; Busby, W.; Wright, G.; Clemmons, D. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc. Natl. Acad. Sci. USA 1993, 90, 10553–10557. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Crossey, P.; Jones, J.; Miell, J. Dysregulation of the insulin/IGF binding protein-1 axis in transgenic mice is associated with hyperinsulinemia and glucose intolerance. Diabetes 2000, 49, 457–465. [Google Scholar] [CrossRef] [Green Version]
- Sehgal, P.; Kumar, N.; Praveen Kumar, V.R.; Patil, S.; Bhattacharya, A.; Vijaya Kumar, M.; Mukherjee, G.; Kondaiah, P. Regulation of protumorigenic pathways by insulin like growth factor binding protein2 and its association along with β-catenin in breast cancer lymph node metastasis. Mol. Cancer 2013, 12, 63. [Google Scholar] [CrossRef] [Green Version]
- Mamdani, H.; Schneider, B.; Perkins, S.M.; Burney, H.N.; Kasi, P.M.; Abushahin, L.I.; Birdas, T.; Kesler, K.; Watkins, T.M.; Badve, S.S.; et al. A phase II trial of adjuvant durvalumab following trimodality therapy for locally advanced esophageal and gastroesophageal junction adenocarcinoma: A big ten cancer research consortium study. Front. Oncol. 2021, 11, 736620. [Google Scholar] [CrossRef]
- van den Ende, T.; de Clercq, N.C.; Henegouwen, M.I.V.B.; Gisbertz, S.S.; Geijsen, E.D.; Verhoeven, R.H.A.; Meijer, S.L.; Schokker, S.; Dings, M.P.G.; Bergman, J.; et al. Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: A single-arm phase II feasibility trial (PERFECT). Clin. Cancer Res. 2021, 27, 3351–3359. [Google Scholar] [CrossRef]
- Seymour, L.; Bogaerts, J.; Perrone, A.; Ford, R.; Schwartz, L.H.; Mandrekar, S.; Lin, N.U.; Litiere, S.; Dancey, J.; Chen, A.; et al. iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017, 18, e143–e152. [Google Scholar] [CrossRef] [Green Version]
- Bray, N.L.; Pimentel, H.; Melsted, P.; Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 2016, 34, 525–527. [Google Scholar] [CrossRef]
- Becht, E.; Giraldo, N.A.; Lacroix, L.; Buttard, B.; Elarouci, N.; Petitprez, F.; Selves, J.; Laurent-Puig, P.; Sautes-Fridman, C.; Fridman, W.H.; et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016, 17, 218. [Google Scholar] [CrossRef]
- Thorsson, V.; Gibbs, D.L.; Brown, S.D.; Wolf, D.; Bortone, D.S.; Ou Yang, T.H.; Porta-Pardo, E.; Gao, G.F.; Plaisier, C.L.; Eddy, J.A.; et al. The immune landscape of cancer. Immunity 2018, 48, 812–830.e14. [Google Scholar] [CrossRef]
- Wang, G.; Chow, R.D.; Zhu, L.; Bai, Z.; Ye, L.; Zhang, F.; Renauer, P.A.; Dong, M.B.; Dai, X.; Zhang, X.; et al. CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade. Cancer Discov. 2020, 10, 1912–1933. [Google Scholar] [CrossRef] [PubMed]
- Shah, M.A.; Kojima, T.; Hochhauser, D.; Enzinger, P.; Raimbourg, J.; Hollebecque, A.; Lordick, F.; Kim, S.B.; Tajika, M.; Kim, H.T.; et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: The phase 2 KEYNOTE-180 study. JAMA Oncol. 2019, 5, 546–550. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marabelle, A.; Le, D.T.; Ascierto, P.A.; Di Giacomo, A.M.; De Jesus-Acosta, A.; Delord, J.P.; Geva, R.; Gottfried, M.; Penel, N.; Hansen, A.R.; et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 2020, 38, 1–10. [Google Scholar] [CrossRef]
- Wang, F.; Wei, X.L.; Wang, F.H.; Xu, N.; Shen, L.; Dai, G.H.; Yuan, X.L.; Chen, Y.; Yang, S.J.; Shi, J.H.; et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann. Oncol. 2019, 30, 1479–1486. [Google Scholar] [CrossRef] [Green Version]
- Rechler, M.M. Insulin-like growth factor binding proteins. Vitam. Horm. 1993, 47, 1–114. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Gao, C.; Cao, F.; Wu, Y.; Chen, S.; Han, X.; Mo, J.; Qiu, Z.; Fan, W.; Zhou, P.; et al. Pan-cancer analysis of IGF-1 and IGF-1R as potential prognostic biomarkers and immunotherapy targets. Front. Oncol. 2021, 11, 755341. [Google Scholar] [CrossRef] [PubMed]
- Wu, Q.; Tian, A.L.; Li, B.; Leduc, M.; Forveille, S.; Hamley, P.; Galloway, W.; Xie, W.; Liu, P.; Zhao, L.; et al. IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms. J. Immunother. Cancer 2021, 9, e002722. [Google Scholar] [CrossRef]
- Ajona, D.; Ortiz-Espinosa, S.; Lozano, T.; Exposito, F.; Calvo, A.; Valencia, K.; Redrado, M.; Remirez, A.; Lecanda, F.; Alignani, D.; et al. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. Nat. Cancer 2020, 1, 75–85. [Google Scholar] [CrossRef] [Green Version]
- Grasso, C.S.; Giannakis, M.; Wells, D.K.; Hamada, T.; Mu, X.J.; Quist, M.; Nowak, J.A.; Nishihara, R.; Qian, Z.R.; Inamura, K.; et al. Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov. 2018, 8, 730–749. [Google Scholar] [CrossRef] [Green Version]
- Hsu, J.M.; Xia, W.; Hsu, Y.H.; Chan, L.C.; Yu, W.H.; Cha, J.H.; Chen, C.T.; Liao, H.W.; Kuo, C.W.; Khoo, K.H.; et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat. Commun. 2018, 9, 1908. [Google Scholar] [CrossRef]
- Zhang, H.; Bi, Y.; Wei, Y.; Liu, J.; Kuerban, K.; Ye, L. Blocking Wnt/beta-catenin signal amplifies anti-PD-1 therapeutic efficacy by inhibiting tumor growth, migration, and promoting immune infiltration in glioblastomas. Mol. Cancer Ther. 2021, 20, 1305–1315. [Google Scholar] [CrossRef] [PubMed]
- McGranahan, N.; Swanton, C. Clonal heterogeneity and tumor evolution: Past, present, and the future. Cell 2017, 168, 613–628. [Google Scholar] [CrossRef] [Green Version]
- Espiritu, S.M.G.; Liu, L.Y.; Rubanova, Y.; Bhandari, V.; Holgersen, E.M.; Szyca, L.M.; Fox, N.S.; Chua, M.L.K.; Yamaguchi, T.N.; Heisler, L.E.; et al. The evolutionary landscape of localized prostate cancers drives clinical aggression. Cell 2018, 173, 1003–1013.e15. [Google Scholar] [CrossRef]
- Yu, T.; Gao, X.; Zheng, Z.; Zhao, X.; Zhang, S.; Li, C.; Liu, G. Intratumor heterogeneity as a prognostic factor in solid tumors: A systematic review and meta-analysis. Front. Oncol. 2021, 11, 744064. [Google Scholar] [CrossRef]
- Saygin, C.; Matei, D.; Majeti, R.; Reizes, O.; Lathia, J. Targeting Cancer Stemness in the Clinic: From Hype to Hope. Cell Stem Cell 2019, 24, 25–40. [Google Scholar] [CrossRef] [Green Version]
- Yi, L.; Huang, P.; Zou, X.; Guo, L.; Gu, Y.; Wen, C.; Wu, G. Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer. Pharmacol. Res. 2020, 161, 105144. [Google Scholar] [CrossRef]
- Alzaid, A.; Castro, R.; Wang, T.; Secombes, C.J.; Boudinot, P.; Macqueen, D.J.; Martin, S.A. Cross talk between growth and immunity: Coupling of the IGF axis to conserved cytokine pathways in rainbow trout. Endocrinology 2016, 157, 1942–1955. [Google Scholar] [CrossRef] [Green Version]
- Chovanec, M.; Cierna, Z.; Miskovska, V.; Machalekova, K.; Kalavska, K.; Rejlekova, K.; Svetlovska, D.; Macak, D.; Spanik, S.; Kajo, K.; et al. betacatenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors. BMC Cancer 2018, 18, 1062. [Google Scholar] [CrossRef] [Green Version]
- Du, L.; Lee, J.H.; Jiang, H.; Wang, C.; Wang, S.; Zheng, Z.; Shao, F.; Xu, D.; Xia, Y.; Li, J.; et al. beta-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion. J. Exp. Med. 2020, 217, e20191115. [Google Scholar] [CrossRef]
- Salmon, H.; Idoyaga, J.; Rahman, A.; Leboeuf, M.; Remark, R.; Jordan, S.; Casanova-Acebes, M.; Khudoynazarova, M.; Agudo, J.; Tung, N.; et al. Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 2016, 44, 924–938. [Google Scholar] [CrossRef]
- Sanchez-Paulete, A.R.; Cueto, F.J.; Martinez-Lopez, M.; Labiano, S.; Morales-Kastresana, A.; Rodriguez-Ruiz, M.E.; Jure-Kunkel, M.; Azpilikueta, A.; Aznar, M.A.; Quetglas, J.I.; et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. 2016, 6, 71–79. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Palucka, K.; Banchereau, J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 2012, 12, 265–277. [Google Scholar] [CrossRef] [PubMed]
- Fucikova, J.; Palova-Jelinkova, L.; Bartunkova, J.; Spisek, R. Induction of tolerance and immunity by dendritic cells: Mechanisms and clinical applications. Front. Immunol. 2019, 10, 2393. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liso, A.; Castellani, S.; Massenzio, F.; Trotta, R.; Pucciarini, A.; Bigerna, B.; De Luca, P.; Zoppoli, P.; Castiglione, F.; Palumbo, M.C.; et al. Human monocyte-derived dendritic cells exposed to hyperthermia show a distinct gene expression profile and selective upregulation of IGFBP6. Oncotarget 2017, 8, 60826–60840. [Google Scholar] [CrossRef] [Green Version]
- Zhou, J.; Cheng, P.; Youn, J.I.; Cotter, M.J.; Gabrilovich, D.I. Notch and wingless signaling cooperate in regulation of dendritic cell differentiation. Immunity 2009, 30, 845–859. [Google Scholar] [CrossRef] [Green Version]
- Hong, Y.; Manoharan, I.; Suryawanshi, A.; Shanmugam, A.; Swafford, D.; Ahmad, S.; Chinnadurai, R.; Manicassamy, B.; He, Y.; Mellor, A.L.; et al. Deletion of LRP5 and LRP6 in dendritic cells enhances antitumor immunity. Oncoimmunology 2016, 5, e1115941. [Google Scholar] [CrossRef] [Green Version]
- Klempner, S.J.; Bendell, J.C.; Villaflor, V.M.; Tenner, L.L.; Stein, S.M.; Rottman, J.B.; Naik, G.S.; Sirard, C.A.; Kagey, M.H.; Chaney, M.F.; et al. Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers. Mol. Cancer Ther. 2021, 20, 2240–2249. [Google Scholar] [CrossRef]
Characteristics | Overall, n = 21 | IGFBP1hiWNT3Alo, n = 7 (%) | Non-IGFBP1hiWNT3Alo, n = 14 (%) | p Value |
---|---|---|---|---|
Sex | 1.000 | |||
Male | 19 | 6 (85.7%) | 13 (92.9%) | |
Female | 2 | 1 (14.3%) | 1 (7.1%) | |
Age, years | ||||
<60 | 12 | 3 (42.9%) | 9 (64.3%) | 0.397 |
≥60 | 9 | 4 (57.1%) | 5 (35.7%) | |
Smoking | 1.000 | |||
No | 5 | 2 (28.6%) | 3 (21.4%) | |
Yes | 16 | 5 (71.4%) | 11 (78.6%) | |
Drinking | 0.354 | |||
No | 6 | 3 (42.9%) | 3 (21.4%) | |
Yes | 15 | 4 (57.1%) | 11 (78.6%) | |
Family history | 0.533 | |||
No | 19 | 7 (100.0%) | 12 (85.7%) | |
Yes | 2 | 0 (0.0%) | 2 (14.3%) | |
Tumor length, cm | 0.656 | |||
≤3 | 8 | 2 (28.6%) | 6 (42.9%) | |
>3 | 13 | 5 (71.4%) | 8 (57.1%) | |
Differentiation | 0.762 | |||
Low | 8 | 2 (28.6%) | 6 (42.9%) | |
Middle | 12 | 5 (71.4%) | 7 (50.0%) | |
High | 1 | 0 (0.0%) | 1 (7.1%) | |
AJCC stage | 1.000 | |||
I+II | 1 | 0 (0.0%) | 1 (7.1%) | |
III+IV | 20 | 7 (100.0%) | 13 (92.9%) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Liu, M.; Yan, W.; Chen, D.; Luo, J.; Dai, L.; Chen, H.; Chen, K.-N. IGFBP1hiWNT3Alo Subtype in Esophageal Cancer Predicts Response and Prolonged Survival with PD-(L)1 Inhibitor. Biology 2022, 11, 1575. https://doi.org/10.3390/biology11111575
Liu M, Yan W, Chen D, Luo J, Dai L, Chen H, Chen K-N. IGFBP1hiWNT3Alo Subtype in Esophageal Cancer Predicts Response and Prolonged Survival with PD-(L)1 Inhibitor. Biology. 2022; 11(11):1575. https://doi.org/10.3390/biology11111575
Chicago/Turabian StyleLiu, Meichen, Wanpu Yan, Dongbo Chen, Jiancheng Luo, Liang Dai, Hongsong Chen, and Ke-Neng Chen. 2022. "IGFBP1hiWNT3Alo Subtype in Esophageal Cancer Predicts Response and Prolonged Survival with PD-(L)1 Inhibitor" Biology 11, no. 11: 1575. https://doi.org/10.3390/biology11111575